1 January 2027
Medicare negotiated prices for 2027 take effect
Discounts of 40% to 71% below list price for these drugs, before the rebates drugmakers already pay.
When does Ibrance go off patent?
In the US, generics can launch from 2027. Ibrance is sold by Pfizer. US patent term extended to March 2027, and pediatric exclusivity to September 2027.
Ibrance's US exclusivity date is based on patent-expiry estimate. It is estimated from patent expiry rather than a fixed entry date, so it may move as patents are challenged or extended. It is a small-molecule drug, so copies are generics. Generic launches usually take most of the US volume within months.
| Patent or protection | Covers | Expiry |
|---|---|---|
| US RE47,739 | Palbociclib itself, with patent term extension | 5 March 2027 |
| Pediatric exclusivity | Adds six months to the patent | 5 September 2027 |
| US 10,723,730 | Solid forms of palbociclib, with pediatric exclusivity | 8 August 2034 |
| Later drug product patent | With pediatric exclusivity | 19 February 2037 |
| Europe and Japan basic patents | Ibrance, per Pfizer | 2028 |
Ibrance's basic US patent, extended to 5 March 2027, now carries six months of pediatric exclusivity, to 5 September 2027. Patents on solid forms and the drug product run to 2034 and 2037. Generic makers have filed since 2019 and Pfizer has settled some cases on undisclosed terms. Pfizer lists 2028 for Europe and Japan, and generics have already entered some markets outside the US.
Sources: FDA Orange Book data files · Pfizer 10-K 2025
| Year | Worldwide | US | Growth |
|---|---|---|---|
| 2022 | $5.12B | $3.37B | – |
| 2023 | $4.75B | $3.15B | -7% |
| 2024 | $4.37B | $2.85B | -8% |
| 2025 | $4.12B | $2.71B | -6% |
Worldwide net sales as reported, with the US share. Sources: Pfizer 10-K 2025 · Pfizer 10-K 2023
Filed with the FDA Generic makers have filed since 2019. Pfizer settled some cases on undisclosed terms, and its patent extension runs to March 2027 and pediatric exclusivity to September 2027.
| Company (product) | Stage |
|---|---|
| Several generic makers (not named by Pfizer) | Filed with the FDA |
Checked October 2026. Sources: Pfizer 10-Q, Q3 2021 · Pfizer: patent extension
Among past small-molecule drugs facing unrestricted generics, US sales in the first full year after copies arrived were a median 18% of the last full year before (range 0% to 48%, 10 drugs), and 6% by the third year (8 drugs). Where settlements limit generic volumes, as with Revlimid, the decline is slower. Every drug is different: settlements, how many copies launch, and pricing all change the curve. See the erosion benchmarks →
| Scenario | 2025 US sales | Year 1 (about 2028) | Year 2 | Year 3 |
|---|---|---|---|---|
| Fastest past case | $2.71B | $0.00B0% | $0.00B0% | $0.02B1% |
| Median | $2.71B | $0.48B18% | $0.19B7% | $0.16B6% |
| Slowest past case | $2.71B | $1.30B48% | $0.67B25% | $0.47B17% |
An illustration, not a forecast: it applies the past-cliff benchmarks to Ibrance's 2025 US sales, held flat until copies arrive in 2027. Year 1 is the first full year with copies on sale.
Ibrance was selected for the Medicare Drug Price Negotiation Program. Its negotiated Medicare price takes effect in 2027, 50% below its list price. That is the same year US generics can launch. The discount is measured against list price, before the rebates drugmakers already pay, and applies to Medicare only, so the revenue impact is smaller than the headline number. See every negotiated Medicare price →
Ibrance is 6.6% of Pfizer's 2025 revenue ($4.1B of $62.6B). With Xtandi, Eliquis, Vyndaqel and Prevnar 20, the drugs tracked here add up to 43% of Pfizer's revenue losing US exclusivity by 2035. Eliquis and Xtandi are Pfizer's reported alliance and product revenue ($8.0B, $2.2B).
Bars show each company's tracked drugs as a share of its total 2025 revenue. Ibrance is highlighted.
Discounts of 40% to 71% below list price for these drugs, before the rebates drugmakers already pay.
The extended basic patent runs to 5 March 2027 and pediatric exclusivity to 5 September 2027. Generic makers have filed since 2019; Pfizer settled some cases on undisclosed terms.